Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Hypertension. 2020 Mar 16;75(5):1251–1259. doi: 10.1161/HYPERTENSIONAHA.119.13922

Table 2.

Baseline and post-treatment assessment

Measure Pre-Treatment Post-Treatment Mean within-subject change p-value
Weight (kg) 87.7 ± 23.0 89.3 ± 22.1 1.6 ± 3.2 0.25
Systolic blood pressure (mmHg) 131.1 ± 10.8 124.3 ± 23.1 −6.9 ± 22.5 0.43
Diastolic blood pressure (mmHg) 81.7 ± 9.0 77. 8 ± 13.8 −3.9 ± 14.2 0.41
Heart Rate (bpm) 61.3 ± 7.2 59.6 ± 6.2 −1.6 ± 4.6 0.30
Serum Potassium (mmol/L) 3.67 ± 0.24 4.12 ± 0.35 0.4 ± 0.5 0.06
Creatinine (mg/dL) 1.09 ± 0.16 1.21 ± 0.38 0.12 ± 0.39 0.35
Glucose, fasting (mmol/L) 5.18 ± 0.60 5.22 ± 0.58 0.0 ± 0.4 0.82
Insulin, fasting (pmol/L) 61.21 ± 16.13 83.18 ± 37.09 22.0 ± 46.7 0.13
C-peptide, fasting (pmol/L) 525.34 ± 105.12 693.59 ± 224.70 168.2 ± 260.5 0.13
C-peptide/Insulin ratio 9.20 ± 2.95 9.11 ± 2.64 −0.1 ± 2.6 1.0
Fructosamine (μmol/L) 461.2±169.1 457.1±101.6 −4.1±94.2 0.94
Aldosterone (ng/dL) 20.4 ± 15.2 6.2 ± 3.7 −14.3 ± 16.6 0.02
11-deoxycorticosterone (pg/mL) 47.4 ± 34.1 16.6 ± 19.3 −30.9 ± 41.3 0.02
Cortisol (μg/dL) 9.7±2.7 9.2±2.6 −0.6±3.4 0.57
Corticotropin (pg/mL) 40.4 ± 7.4 46.6 ± 16.0 6.2 ± 12.9 0.25
Resting Energy Expenditure (kcal/day) 1723 ± 434 1597 ± 284 −126 ± 207 0.15
Respiratory Quotient 0.81 ± 0.04 0.84 ± 0.07 0.03 ± 0.04 0.14
DEXA Measurements
 Fat free mass (kg) 53.6 ± 13.9 53.9 ± 13.9 0.3 ± 1.8 0.65
 Fat mass (kg) 30.9 ± 12.4 32.3 ± 12.0 14.7 ± 2.1 0.07
 fat (%) 35.3 ± 6.5 36.7 ± 6.5 1.4 ± 1.8 0.06
 fat, Gynoid (%) 39.0 ± 9.0 39.2 ± 9.9 0.1 ± 2.1 1.0
 fat, Android (%) 40.4 ± 9.2 43.2 ± 9.7 2.8 ± 2.6 0.02
 fat Android/Gynoid ratio 1.07 ± 0.30 1.15 ± 0.35 0.08 ± 0.07 0.004

Results are mean ± SD. Wilcoxon signed-rank test

Average results reported for variables that were assessed on both study days (blood pressure, heart rate, glucose, insulin C-peptide, and insulin/C-peptide ratio).